The investigational drug, VX-770, appeared to improve function of what is known as CFTR--the faulty protein responsible for CF. It is among the first compounds being developed for CF that specifically targets the root cause of cystic fibrosis.
Patients who took VX-770 for 28 days showed improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels. Excessive sweat chloride is a key clinical indicator of CF. The sweat test is the traditional diagnostic test for CF.
"Patients with CF have a defective protein in chloride channels in lung cells that, in effect, causes a door to shut too tightly, ultimately leading to severe infections in the lung" said Steven M. Rowe, M.D., M.S.P.H, assistant professor of medicine at the University of Alabama at Birmingham and lead investigator at the UAB site, one of 16 study sites nationwide for this VX-770 trial. "The data suggest that the drug seems to improve the function of the protein, so that the door opens and closes more properly." UAB also served as the central coordinating center for nasal potential difference testing, an important outcome measure in the trial.
VX-770 was developed by Vertex Pharmaceuticals, in conjunction with the Cystic Fibrosis Foundation, using a cutting-edge technology known as high-throughput screening, an advanced technique for drug discovery. UAB's Gregory Fleming James Cystic Fibrosis Research Center was the first site in the nation to clinically administer VX-770 to CF patients in the trial in May 2007.
Investigators studied 39 patients with CF in the trial who had a specific mutation in the gene known to cause CF. The primary objective of the trial was to demonstrate the safety and tolerability of VX-770. All patients in the trial completed use of the study drug, and adverse events were similar to placebo.
"Nearly a decade ago, the CF Foundation recognized the need to develop new therapies that address the underlying cause of CF and not just the symptoms of the disease. We are encouraged by the data from this Phase 2 trial and see the trial as a milestone in our efforts to discover and develop new treatment options for this disease," said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation.
VX-770 is currently in Phase 3 clinical trials for cystic fibrosis, and, pending data from these studies, Vertex anticipates submitting a new drug application to the FDA in the second half of 2011.
CF is a fatal genetic disease that affects about 30,000 people in the United States and 70,000 worldwide. It is caused by a genetic mutation that causes life-threatening lung infections and premature death. Ten million Americans are symptomless carriers of a defective CF gene.
Other collaborators on the study are the University of Colorado, Denver and Children's Hospital, Aurora; Johns Hopkins Medical Institutions; University of Minnesota; Hospital for Sick Children and the University of Toronto; University of Iowa; Children's Hospital and Case Western Reserve University School of Medicine, Cleveland; University of North Carolina; Stanford University School of Medicine; University of Pittsburgh; Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine; Children's Hospital Boston and Beth Israel Deaconess Medical Center; University of Washington and Seattle Children's Hospital.
Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham (UAB) is the state of Alabama's largest employer and an internationally renowned research university and academic health center; its professional schools and specialty patient-care programs are consistently ranked among the nation's top 50. Find more information at www.uab.edu and www.uabmedicine.org.
EDITOR'S NOTE: The University of Alabama at Birmingham (UAB) is a separate, independent institution from the University of Alabama, which is located in Tuscaloosa. Please use University of Alabama at Birmingham on first reference and UAB on second reference.
VIDEO: www.youtube.com/uabnews TEXT: www.uab.edu/news TWEETS: www.twitter.com/uabnews
Bob Shepard | EurekAlert!
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy